Magazines In Improbable, And Perhaps Irreproducible, Clash

Imagine it as F. Lee Bailey meets Albert Einstein, with David Letterman hovering in the background. The Annals of Improbable Research (AIR) and the Journal of Irreproducible Results (JIR), two of a handful of publications that take an intentionally humorous view of science and scientists, are moving slowly toward a date in court. George H. Scherr, publisher of JIR, is suing Marc Abrahams, editor of AIR, and Improbable Research Inc., AIR's parent company, for what Scherr claims is unfair competi

Written byPeter Gwynne
| 6 min read

Register for free to listen to this article
Listen with Speechify
0:00
6:00
Share

Imagine it as F. Lee Bailey meets Albert Einstein, with David Letterman hovering in the background. The Annals of Improbable Research (AIR) and the Journal of Irreproducible Results (JIR), two of a handful of publications that take an intentionally humorous view of science and scientists, are moving slowly toward a date in court. George H. Scherr, publisher of JIR, is suing Marc Abrahams, editor of AIR, and Improbable Research Inc., AIR's parent company, for what Scherr claims is unfair competition, deceptive trade practices, and trademark infringement.

The case has everything that addicts of Court TV have come to expect in big trials, and more: a claim for significant damages, originally to the tune of $4.2 million with a recent increase to $8.1 million; a charge of racketeering; a 1.5-inch-thick complaint document, including exhibits; an assertion of ownership of an event, the Ig Nobel Prizes, that has gained a stellar reputation ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies